Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDC-1421 for Treating Depression in Cancer Patients
NCT03833206Phase 2Not yet recruiting
- Start
- Jan 2027
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of PDC-1421 in major depressive disorder (MDD) (2 arms). Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 5 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
PDC-1421
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03833206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03833206.